South Korea’s Samsung Group is in talks to buy U.S.-based drugmaker Biogen, according to Korea Economic Daily’s Jae-young Han, Ju-hyun Lee, In-seol Jeong and Hyung-suk Song, citing investment banking sources. The biotechnology firm approached Samsung to sell its shares, which could be valued at more than $42B, including a control premium, according to the report, which cited a global investment bank senior official as having said: “Samsung is at the negotiating table with the sell side to acquire Biogen.” Following the publication of the report, Biogen shares are up 9%, or $22.64, to $258.63 in afternoon trading.